OncoMatch/Clinical Trials/NCT07170995
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Is NCT07170995 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including SHR-8068，adebelizumab and platinum-based chemotherapy and tislelizumab, and platinum-based chemotherapy for advanced or metastatic non-small cell lung cancer.
Treatment: SHR-8068，adebelizumab and platinum-based chemotherapy · tislelizumab, and platinum-based chemotherapy — This study is a randomized, open-label, controlled, multicenter Phase III clinical trial to evaluate the efficacy and safety of SHR-8068 combined with adebrelimab and platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify